Navigation Links
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Date:9/25/2008

y authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel or NGX426 will successfully treat migraine and/or other indications for which they are developed, that the End of Phase II meeting will be held in the anticipated time frame, that NGX267 will successfully treat xerostomia secondary to Sjogren's syndrome, that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel, NGX426 or NGX267 or that TorreyPines will be able to reach agreement with a partner for any of the product candidates or programs on terms that are acceptable to TorreyPines. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact:

Craig Johnson

TorreyPines Therapeutics, Inc.

858-623-5665, x158

cjohnson@torreypinestherapeutics.com

Media Contact:

David Schull

Russo Partners, LLC

212-845-4271

david.schull@russopartners.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@RxIR.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
(Date:7/29/2015)... ... 2015 , ... Finding gooey or crusty material in the corner of your ... considerable number of terms in popular use to describe it, ophthalmologists call it “gound” ... mucus, blood cells, skin cells and dust, but until now there has been virtually ...
(Date:7/29/2015)... ... 2015 , ... Rainbow Scientific, Inc. (RSI), a North American ... BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC go ... complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3
... , , , , , ... -- China,Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; "China ... and,retailer of Chinese traditional medicines, pharmaceutical products, natural,health products, ... The Company today announced that it had opened three ...
... , , REHOVOT, Israel, December ... acute ischemic stroke into its,Phase III clinical study of DP-b99 ... Center, Israel. The MACSI trial involves,numerous medical centers in the ... is D-Pharm,s most advanced product developed,for protection of brain cells ...
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ -- China Cord ... ), China,s leading provider of cord blood collection, laboratory testing, ... announced that the underwriters of its recent public offering of ... which will result in the issuance of an additional 314,867 ...
Cached Biology Technology:China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base 2China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base 3D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... common with serial killers? Refined hunting skills, according to a ... Journal of Zoology . A team of US-based researchers ... just like serial criminals. Using the same methods used ... technique usually used to hunt serial criminals, can be used ...
... the University of California, Davis , who discovered a ... a three-year $750,000 grant from the American Asthma , ... asthma, a , chronic disease affecting 300 million people ... study, we propose to evaluate whether the new field ...
... in the flow of the Apalachicola River have far-reaching ... reef fish populations in the northeastern Gulf of Mexico, ... may provide new ammunition for states engaged in a ... found that in years with low river flow, the ...
Cached Biology News:UC Davis grant zeroes in on novel asthma diagnosis and treatment 2UC Davis grant zeroes in on novel asthma diagnosis and treatment 3Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 2Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 3
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Request Info...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Biology Products: